{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T21:06:16Z","timestamp":1765487176212,"version":"3.41.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jcf.2024.11.010","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T12:31:30Z","timestamp":1733401890000},"page":"548-551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment effects of elexacaftor\/tezacaftor\/ivacaftor on people with cystic fibrosis heterozygous for 3849+10kbC->T and a class I variant"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8073-3973","authenticated-orcid":false,"given":"Moshe","family":"Heching","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Shteinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6259-405X","authenticated-orcid":false,"given":"Inbal","family":"Golan-Tripto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3132-7746","authenticated-orcid":false,"given":"Galit","family":"Livnat-Levanon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9591-9882","authenticated-orcid":false,"given":"Karin","family":"Yaacoby-Bianu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liora","family":"Boehm Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7372-6262","authenticated-orcid":false,"given":"Guy","family":"Hazan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liora","family":"Slomianski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Prais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8840-5958","authenticated-orcid":false,"given":"Huda","family":"Mussaffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mordechai R","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jcf.2024.11.010_bib0001","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/jcm11041021","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation and advanced lung disease: a 48-week observational study","volume":"11","author":"Carnovale","year":"2022","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.jcf.2024.11.010_bib0002","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"PROMISE Study group. Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.11.010_bib0003","unstructured":"TRIKAFTA prescribing information. Available from: June 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s004lbl.pdf."},{"key":"10.1016\/j.jcf.2024.11.010_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107406","article-title":"Long-term clinical outcomes of elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis and advanced pulmonary disease","volume":"219","author":"Savi","year":"2023","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.11.010_bib0005","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2022.10.011","article-title":"Treatment effects of elexacaftor\/tezacaftor\/ivacaftor in people with CF carrying non-F508del mutations","volume":"22","author":"Livnat","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.jcf.2024.11.010_bib0006","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"French Cystic Fibrosis Reference Network study group. The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"15","key":"10.1016\/j.jcf.2024.11.010_bib0007","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM199410133311503","article-title":"A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations","volume":"331","author":"Highsmith","year":"1994","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.11.010_bib0008","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1183\/09031936.05.10100004","article-title":"The CFTR 3849+10kbC->T and 2789+5G->A alleles are associated with a mild CF phenotype","volume":"25","author":"Dugu\u00e9p\u00e9roux","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2024.11.010_bib0009","unstructured":"CFTR2 database, https:\/\/cftr2.org\/mutation\/general\/3849%252B10kbC-%253ET\/W1282X, accessed June 16, 2024."},{"key":"10.1016\/j.jcf.2024.11.010_bib0010","unstructured":"KALYDECO prescribing information. Available from: May 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/203188s038lbl.pdf."},{"key":"10.1016\/j.jcf.2024.11.010_bib0011","unstructured":"SYMDEKO prescribing information. Available from: February 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210491lbl.pdf."},{"issue":"1","key":"10.1016\/j.jcf.2024.11.010_bib0012","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01959-2023","article-title":"Gathering real-world compassionate data to expand eligibility for elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint","volume":"63","author":"Burgel","year":"2024","journal-title":"Eur Respir J"},{"issue":"10212","key":"10.1016\/j.jcf.2024.11.010_bib0013","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.11.010_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.06.001","article-title":"Clinical and functional efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis carrying the N1303K mutation","author":"Sadras","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.11.010_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.02.008","article-title":"Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation","author":"Aluma","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.11.010_bib0016","article-title":"Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis","volume":"40","author":"Stekolchik","year":"2022","journal-title":"Respir Med Case Rep"},{"issue":"8970","key":"10.1016\/j.jcf.2024.11.010_bib0017","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0140-6736(95)92165-6","article-title":"3849+10 kb C\u2013>T mutation and disease severity in cystic fibrosis","volume":"346","author":"Stern","year":"1995","journal-title":"Lancet"},{"issue":"8862","key":"10.1016\/j.jcf.2024.11.010_bib0018","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0140-6736(93)91885-P","article-title":"Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C\u2013>T mutation","volume":"342","author":"Augarten","year":"1993","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jcf.2024.11.010_bib0019","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1513\/AnnalsATS.202006-659OC","article-title":"Ivacaftor in people with cystic fibrosis and a 3849+10kb C\u2192T or D1152H residual function mutation","volume":"18","author":"Kerem","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.jcf.2024.11.010_bib0020","doi-asserted-by":"crossref","first-page":"19810","DOI":"10.1038\/s41598-021-99184-1","article-title":"Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment","volume":"11","author":"Shaughnessy","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jcf.2024.11.010_bib0021","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02774-2020","article-title":"Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator","volume":"57","author":"Laselva","year":"2021","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jcf.2024.11.010_bib0022","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jcf.2021.03.011","article-title":"Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR","volume":"20","author":"Veit","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"Supplement 1","key":"10.1016\/j.jcf.2024.11.010_bib0023","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S1569-1993(24)00144-9","article-title":"WS06.05 Long-term outcomes in people with CF lacking early spirometry response to elexacaftor\/tezacaftor\/ivacaftor therapy [Abstract]","volume":"23","author":"Hadhud","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"Supplement 1","key":"10.1016\/j.jcf.2024.11.010_bib0024","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S1569-1993(24)00142-5","article-title":"WS06.03 Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor (ELX\/TEZ\/IVA) in people with cystic fibrosis and ELX\/TEZ\/IVA-responsive, non-F508del genotypes: a phase 3, randomised, placebo-controlled trial [Abstract]","volume":"23","author":"Castellani","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.11.010_bib0025","article-title":"Elexacaftor\/tezacaftor\/ivacaftor efficacy in intestinal organoids with rare CFTR variants in comparison to CFTR-F508del and CFTR-wild type controls","author":"Kroes","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.11.010_bib0026","article-title":"A phase I study assessing the safety and tolerability of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T","author":"Caraco","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.11.010_bib0027","unstructured":"Safety, tolerability, pharmacokinetics, and preliminary efficacy of SPL84 in patients with cystic fibrosis, ClinicalTrials.gov ID NCT06429176. https:\/\/clinicaltrials.gov\/expert-search?term=NCT06429176, accessed November 18, 2024."}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324018459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324018459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T20:28:31Z","timestamp":1748982511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324018459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1569199324018459"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.11.010","relation":{},"ISSN":["1569-1993"],"issn-type":[{"type":"print","value":"1569-1993"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment effects of elexacaftor\/tezacaftor\/ivacaftor on people with cystic fibrosis heterozygous for 3849+10kbC->T and a class I variant","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}